CD274 and non-small cell lung carcinoma: First-line anti-PD-L1/PD-1 immune checkpoint inhibitors (anti-PD-(L)1 ICIs) with or without chemotherapy are standard of care for patients with advanced NSCLC without actionable genomic aberrations.1